Integrated BioPharma Q2 fiscal 2025 revenue up 6.1% to $13.9M, net income $0.6M

INTEGRATED BIOPHARMA INC

2025-Q3 EPS reported $0.03 revenue$40,178,000

Revenue $13.9M vs $13.1M YoY; nine-month revenue $40.2M (+6.9%).
Operating income $0.7M vs $0.4M; nine-month operating income $1.4M vs loss $0.2M.
Net income $0.02 EPS vs $0.01; nine-month net income $1.0M ($0.03 EPS) vs loss $0.2M.
Two largest customers in contract manufacturing represented 83% of total revenue in nine-month period.
Co-CEOs cite customer base expansion and revenue growth from core business.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.